UNITED STATES DISTRICT COURT FOR 

THE DISTRICT OF NEW HAMPSHIRE 

IMS HEALTH INCORPORATED, a Delaware ) 

corporation; and VERISPAN, LLC, a Delaware ) 

limited liability company, ) 

 ) 

 Plaintiffs, ) 

 ) 

vs. ) Case No. 06-CV-280-PB 

 ) 

KELLY A. AYOTTE, as Attorney General of ) 

the State of New Hampshire, ) 

 ) 

 Defendant. ) 

 ) 

Declaration of Thomas P. Wharton Jr., M.D., F.A.C.C 

in Support of Plaintiffs’ Motion for Preliminary Injunction

I, Thomas P. Wharton, Jr., M.D., F.A.C.C, hereby declare under penalty of 

perjury that the following is true and correct: 

1. I am over 18 years of age and have personal knowledge of the information 

provided in this declaration. 

2. I am a licensed medical doctor practicing at Exeter, New Hampshire. My 

practice specializes in cardiology. I have practiced in this capacity for 30 years. A copy 

of my curriculum vitae is attached. 

 3. I am chief of the Section of Cardiology and Director of the Cardiac 

Catheterization Laboratory at Exeter Hospital in New Hampshire. 

 4. I am a former Governor of the New Hampshire Chapter of the American 

College of Cardiology and past President of the Tri-State Chapter of the American 

College of Cardiology. I have been practicing cardiology in Exeter and Portsmouth, New 

Hampshire, since 1991 when I moved to New Hampshire from Boston. 
2 

 5. I have conducted several studies of angioplasty as treatment for heart 

attacks at community hospitals, and have written numerous papers and textbook chapters. 

I have lectured widely in the U.S. and abroad, and have contributed to setting up many 

new angioplasty programs for heart attack patients at community hospitals. 

 6. I have worked with many cardiologists in several states and countries who 

are changing local regulations to improve the delivery of primary angioplasty to the 

community. 

 7. I received a bachelor of science degree, magna cum laude, from Yale 

University in 1967 and an M.D. from Washington University School of Medicine, St. 

Louis in 1971. 

 8. I trained at the Brigham and Women’s Hospital in Boston. 

 9. Before accepting the position at Exeter Hospital, I was an interventional 

cardiologist at St. Elizabeth’s Hospital in Boston, where I was Assistant Professor of 

Medicine at Tufts University. 

 10. I have not asked the American Medical Association to prevent the 

disclosure of my prescription data to pharmaceutical company sales representatives 

through the AMA’s Prescribing Data Restriction Program. 

 11. As part of my practice, I receive approximately 50 patients per week, most 

of whom live in the state New Hampshire. The majority of my patients are individuals 

who suffer from cardiovascular disorders. 

 12. On average, I write approximately 50 prescriptions per week. Prescription 

writing generally occurs at the end of a patient encounter and must be done expeditiously, 

given the high number of patients who need medical assistance. Prescription writing is a 
3 

complex task because the task demands both detailed knowledge of the patient's care and 

of drug usage, drug interactions, and current national Practice Guidelines for appropriate 

treatment of cardiovascular disorders. Treatment protocols are increasingly complex, and 

healthcare providers, like myself, are responsible for ensuring that medications are 

prescribed appropriately and without adverse interactions. My goal is always to prescribe 

the most appropriate, disease-specific medication in a safe and cost-effective manner. To 

do this, I must be able to prescribe in the context of all medications a patient takes, 

including those prescribed by other physicians in the community. In addition to 

indications, contraindications, and potential side effects, I must also be aware of drugdrug, drug-age, drug-allergy interactions, and which medications are covered by the 

patient's insurance. This process has become increasingly complex over the years, as the 

number of new medications increases each year with new entries for each class of drugs 

and new classes for each disease, and as treatment Guidelines are continually updated. 

Each drug has its unique indications, contraindications, cross reactivity, complications, 

and costs. 

 13. The decision on which drug to prescribe to a particular patient is dictated 

by my past experiences with using the drugs, coupled with unbiased information about 

them from reliable sources, such as reports from medical journals, and Practice 

Guidelines issued by the American College of Cardiology, the American Heart 

Association, and other medical organizations. In addition, I welcome information given 

to me by pharmaceutical sales representatives who visit my office on a regular basis. I 

recognize that pharmaceutical sales representatives are attempting to make a profit for 

their employers, but they often have excellent information about the products they are 
4 

selling, including specific testing information that I might not otherwise learn about, 

recent reports of scientific studies in peer-reviewed medical journals, and recent updates 

of national Guidelines. They also provide FDA-mandated prescribing information for all 

drugs they discuss. I have found the information they provide to be a valuable additional 

source of information about new drugs that I use in combination with my experience and 

my academic knowledge. In my practice, I and my 4 other cardiologist partners interact 

with sales representatives approximately twice a week and find the discussions 

intellectually stimulating because they often make me aware of very good data which has 

been recently published in peer-reviewed medical journals that challenges my thinking 

about what I should prescribe. In these discussions, my partners and I exchange 

information and challenge each other and the pharmaceutical representatives about our 

respective practice patterns. These discussions are always educational. I try to stay 

current in terms of new developments, but there is so much literature available that it is 

difficult to stay on top of all new developments. I can provide numerous specific 

examples of how pharmaceutical sales representatives have been helpful to me and my 

partners in calling new scientific and economic information and new Guidelines to our 

attention. In my opinion, the patient always wins when I make decisions about their 

health based on multiple sources of the most up-to-date published scientific information 

and the latest information on drug cost and formulary status rather than based on limited 

or absent information. I do not believe that my professional judgment is negatively 

affected or impaired when I consider the published information, Practice Guidelines, and 

local cost and formulary data given to me by pharmaceutical sales representatives. Mere 

sales pitches can not and do not influence me or the physicians I know to start prescribing 
5 

drugs. 

 14. Whenever I instruct a patient to switch from using a generic drug to a new 

drug, I do so based on my professional judgment that the new drug will work better than 

the old drugs in terms of benefit, relief, side effects and long-term overall costeffectiveness. I do not switch from one drug to another solely on the basis of sales 

pitches. 

 15. I understand that pharmaceutical sales representatives who visit my office 

are familiar with my prescribing behavior because information about the prescriptions I 

write is sold by the pharmacies who fill my patients’ prescriptions to third parties and that 

the sales representatives use that information in framing their presentations to me. I 

believe that this is very useful because it allows pharmaceutical companies and their sales 

representatives to inform me about whether I am at any given time prescribing products 

that may be less effective, less safe, less economical, or not in compliance with current 

Practice Guidelines compared to newer products that may be more effective, safer, more 

economical, or more in compliance with Practice Guidelines. Some of the drugs that the 

pharmaceutical companies have developed in recent times are nothing less than 

miraculous in terms of the outcomes that they produce. It is critical for doctors to learn 

about the latest studies and Guidelines in support of these products as soon as possible so 

that they can decide whether they are appropriate for their patients. I believe that this can 

be facilitated when sales representatives have complete information about not only my 

prescribing practices, but also about the prescribing practices of my peers. I also believe 

that many of the physicians that refuse to interact with sales representatives may be 

generally less-informed about current advances in pharmacology and slower to adopt the 
6 

newest best practices. 

 16. In the course of my practice, I have discussed with many other medical 

doctors in the specialty of cardiology and in many other medical specialties their 

experiences with sales representatives from pharmaceutical companies and through this 

contact have formed an opinion that medical doctors: 

 a. Do and should rely on numerous sources of information in order to 

make prescription decisions. Pharmaceutical company sales representatives are just one 

of these many sources. 

 b. Do and should find it useful that pharmaceutical sales 

representatives can access data regarding their individual prescribing practices because 

this (1) helps to ensure that the sales representatives are providing doctors only with 

information about products that are relevant to their practices, and (2) helps point out to 

doctors if they may be prescribing products that are not as useful to patient health or as 

economical or as consistent with the latest Practice Guidelines as other products. 

 c. Are not in any way more easily influenced by pharmaceutical sales 

representatives to prescribe drugs that are not in the doctors’ patients best interests 

because the sales representatives are able to access information about individual doctors’ 

prescribing practices. Doctors are professionally, ethically and legally obligated to make 

decisions that are in the best interest of the patient based on the most up-to-date scientific 

and economic information. Doctors are likewise obligated to do everything they can to 

stay abreast of this most current information. 

 d. Do not and should not expect that information in their prescriptions 

about their prescribing practices will be kept private. Just the opposite, they do and 
7 

should expect that their patients will share the information with the patients’ other 

physicians, and with friends, family, and others; that third party payors will track their 

utilization of guidelines-based therapies in each individual insured patients, that 

pharmacies and other similar entities will make the information available to health 

information companies that aggregate, analyze, and sell the data for research purposes, 

and that the data will be made widely available to academic researchers, government 

agencies, pharmaceutical companies and other entities interested in understanding and 

improving public health. Doctors who do not share these expectations, in my opinion, 

are not fulfilling their professional obligation to put their patients’ and the public’s 

interest in better healthcare above their own interests in maintaining the privacy of their 

prescription decisions. 

 Executed on __July 20___________, 2006, in North Hampton, New Hampshire. 

 s/ Thos. Wharton 

 Thomas P. Wharton Jr., M.D., F.A.C.C. 
TPW 04/13/06 

CURRICULUM VITAE

THOMAS PARKER WHARTON JR, MD, FACC, FSCAI 

EXETER CARDIOVASCULAR ASSOCIATES

PERRY MEDICAL BUILDING, SUITE 101 

3 ALUMNI DRIVE, EXETER, NH. 03833 

Education: 

1971 M.D.—Washington University School of Medicine, St. Louis, Missouri 

1967 B.S. —Yale University [Magna Cum Laude], Engineering and Applied Science 

Postgraduate Training: 

1975-76 Research Fellow in Cardiology, Peter Bent Brigham Hospital, Boston, MA 

1974-75 Clinical Fellow in Cardiology, Peter Bent Brigham Hospital, Boston, MA 

1972-74 Resident in Internal Medicine, Peter Bent Brigham Hospital, Boston, MA 

1971-72 Intern in Internal Medicine, Peter Bent Brigham Hospital, Boston, MA 

Certification: 

2003 Diplomate, American Board of Internal Medicine, Subspecialty of 

 Interventional Cardiology 

1977 Diplomate, American Board of Internal Medicine, Subspecialty of 

 Cardiovascular Disease 

1974 Diplomate, American Board of Internal Medicine 

1972 Diplomate, National Board of Medical Examiners 

Licensure: 

1991 New Hampshire License No. 8652 

1971 Massachusetts License No. 36500 

Current Appointments: 

1999- Chief, Section of Cardiology, Exeter Hospital, Exeter, NH 

1996- Staff Cardiologist, Frisbie Memorial Hospital, Rochester, NH 

1992- Director, Cardiac Catheterization Laboratory, Exeter Hospital, Exeter, NH 

1991- Staff Cardiologist, Portsmouth Regional Hospital, Portsmouth, NH 

Previous Appointments: 

1991-95 Medical Director, Cardiac Rehabilitation Program, Exeter Hospital, Exeter, NH 

1991-99 Staff Cardiologist, Catholic Medical Center, Manchester, NH 

1982-91 Director, Cardiac Rehabilitation Program, St. Elizabeth's Hospital, Boston, MA 

1985-91 Associate Director, Cardiac Catheterization Laboratory, St. Elizabeth's Hospital, Boston, 

MA 

1976-91 Assistant Professor of Medicine, Tufts University School of Medicine, 

 Boston, MA 
PAGE 9 OF 21 

TPW 04/13/06 

1976-82 Director, Cardiac Catheterization Laboratory, U.S. Veterans Administration Medical 

Center, Boston, MA 

1977-82 Lecturer in Medicine, Boston University School of Medicine, Boston, MA 

Memberships and Leadership Positions: 

2004- New Hampshire Medical Society 

2003- Fellow, Society for Cardiovascular Angiography and Interventions 

1999-2002 Governor, New Hampshire Chapter, American College of Cardiology 

2000-2001 President, Northern New England Tri-State Chapter, American College of Cardiology 

1999-2000 Secretary-Treasurer, Northern New England Tri-State Chapter, American College of 

Cardiology 

1996- Fellow, American College of Cardiology 

1974- American Heart Association 

1986-92 Massachusetts Medical Society 

1986-93 American Medical Association 

1968- Southern Medical Society 

Committees: 

2002- Quality Assurance Committee, Exeter Hospital, Exeter, NH 

2002- Political Action Committee, American College of Cardiology 

2002- Board of Governors Nominating Committee, American College of Cardiology 

2000-2002 Coding and Nomenclature Committee, American College of Cardiology 

1999-2002 State Government Relations Subcommittee, American College of Cardiology 

1996-2001 Coronary Unit Design Committee, Exeter Hospital 

1994-1998 Technology Assessment Group, Exeter Hospital 

1992-93 Procedure Review Committee, Exeter Hospital 

1991-92 Intensive Care Unit Committee, Portsmouth Regional Hospital 

1990-91 Grievance Committee, Tufts University School of Medicine 

1990-91 Quality Assurance Committee, St. Elizabeth's Hospital 

1989-92 Human Studies Committee, St. Elizabeth's Hospital 

1987-89 Chairman, Code-99 Review Committee, St. Elizabeth's Hospital 

Honors and Awards: 

2006 Tied for “Top Cardiologist,” New Hampshire Magazine poll of NH physicians. 

2005-06 Selected by peers for “Best Doctors in America” database, awarded to 4% of US 

physicians by nationwide physician survey. 

2004 Tied for “Top Cardiologist,” New Hampshire Magazine poll of NH physicians. 

1975-76 NIH Individual Research Fellowship Award, Internal Medicine 

1971 Alpha Omega Alpha Honor Medical Society, Washington University 

1971 Medical Fund Society Prize in Medicine, Washington University 

1967-71 Jackson Johnson Regional Scholarship, Washington University 

1967 Magna Cum Laude, Yale University 

1966 Phi Beta Kappa, Yale University (President, Senior Year) 

1964 New York Yale Club Award -- Top Ten, Freshman Class 
PAGE 10 OF 21 

TPW 04/13/06 

Other Professional and Academic Activities: 

1. National Associate Investigator, AIR PAMI/NO S.O.S Infarct Angioplasty Protocol, and Principal 

Investigator, Exeter and Portsmouth Regional Hospitals, Exeter and Portsmouth, NH 

2. Principal Investigator, PAMI -2 Infarct Angioplasty Protocol, Exeter and Portsmouth Regional 

Hospitals, Exeter and Portsmouth, NH 

3. Principal Investigator, GUSTO Thrombolysis-MI Protocol,St. Elizabeth’s Hospital, Boston,MA 

4. Principal Investigator, ISIS-3 Thrombolysis-MI Protocol, St. Elizabeth’s Hospital, Boston, MA 

5. Principal Investigator, ProUrokinase Thrombolysis-MI Protocols (2), St. Elizabeth’s Hospital, 

Boston, MA 

6. Lecturer, Physical Diagnosis Course, Tufts University, Boston, MA; 1990. 

7. EKG Course for medical students and hospital residents, Tufts University, Boston, MA; 1982-

1991. 

8. Consultant, Doylestown Hospital, Doylestown PA, regarding petition to the State of Pennsylvania 

Department of Health to revise state regulations prohibiting the performance of primary 

angioplasty at non-surgical hospitals, 1997. 

9. Consultant, Overlook Hospital, Summit, NJ, regarding petition to the State of New Jersey 

Department of Health to provide exemption to Overlook Hospital from state regulations 

prohibiting the performance of primary angioplasty at non-surgical hospitals, 1998. 

10. Consultant, Country of Holland, regarding writing national regulations for the performance of 

primary angioplasty at non-surgical hospitals 1998. 

11. Chairman, Interventional Cardiology: Controlling Costs and Improving Outcomes. Cambridge 

Health Resources Symposium, Orlando, FL, January 25-26, 1999. 

12. Consultant, Jane Phillips Medical Center, Bartlesville, OK, regarding evaluation of their 

interventional program without cardiac surgery on site, 2000. 

13. Peer reviewer, ACC/AHA Guidelines for PCI, 2001 Revision. 

14. Primary reviewer, ACC Clinical Expert Consensus Document, “Standards for Acquisition, 

Measurement, and Reporting on Intravascular Ultrasound Studies,” 2000. 

15. Consultant, Waterbury Health Care, Waterbury, CT, regarding their application for a Certificate of 

Need to perform primary and elective PTCA at two Waterbury hospitals without on-site cardiac 

surgery, 2000. 
PAGE 11 OF 21 

TPW 04/13/06 

16. Peer reviewer, Cardiac Care Network of Ontario Report of Expert Panel on Invasive Cardiology, 

2001. 

17. Consultant, Bon Secours Hospital, Venice, FL, regarding their application for a Certificate of 

Need to perform cardiac surgery, 2001. 

18. Consultant, Martin Memorial Hospital, Stuart, FL, regarding their application for a Certificate of 

Need to perform cardiac surgery, 2001. 

19. Consultant, New Jersey Department of Health, regarding standards for primary and elective PTCA 

at New Jersey hospitals without onsite cardiac surgery, 2001. 

20. Consultant, DataScope Corporation, 2001 - present. 

21. Consultant, Accumetrics Corporation, 2001. 

22. Consultant, Michigan Primary Angioplasty Coalition, regarding their application to the Certificate 

of Need Committee of the Michigan Department of Health to modify standards for primary PTCA 

at hospitals without onsite cardiac surgery, 2001. 

23. Editorial Board, Critical Pathways in Cardiology Journal, 2001 to present. 

24. Consultant, coalition of Pennsylvania Hospitals without onsite cardiac surgery, regarding their 

application for a variance to state statute which would permit primary PTCA, 2002. 

25. Consultant, Verde Valley Medical Center, Cottonwood, AZ, regarding evaluation of their 

interventional program without cardiac surgery on site, 2002. 

26. Consultant, Uniontown Hospital, Uniontown PA, helping them to establish and implement a 

program to provide emergent and elective coronary intervention at a hospital with off-site cardiac 

surgical backup, 2002. 

27. Consultant, Maryland Health Care Commission, which is considering changes to the state’s policy 

on PCI: 1) use of primary PCI at community hospitals, 2) changing EMS transfer schemes to 

triage patients to primary PCI hospitals, and 3) performance of elective PCI at hospitals without 

surgical backup. 2003. 

28. Consultant, Herman Hospitals Network, Houston, TX, regarding establishing primary and elective 

PTCA programs, 2003. 

29. External reviewer, Pascack Valley Hospital, Westwood, NJ, to evaluate the overall quality of care 

and performance of their facility and staff in providing full cardiac catheterization services. 

30. Consultant, PCI Project, United Hospital Center, Clarksburg, WV, helping to establish and 

implement a program to provide emergent and elective coronary intervention at a hospital with 

off-site cardiac surgical backup, 2003. 
PAGE 12 OF 21 

TPW 04/13/06 

31. Consultant, Community Hospitals of Ohio, in their petition to the state to grant Certificates of 

Need for qualified community hospitals to perform coronary intervention, 2003. 

32. External reviewer, Overlook Hospital, Summit, NJ, (1) to evaluate the overall quality of care and 

performance of their facility and staff in providing full cardiac catheterization services, and (2) to 

evaluate the performance and outcomes of their acute coronary intervention program. 2003. 

33. Consultant, South Metro Hospital, Denver, CO, regarding establishing and implementing a 

program to provide emergent and elective coronary intervention at a hospital with off-site cardiac 

surgical backup, 2003. 

34. Consultant, Lawrence Memorial Hospital, Lawrence, Kansas, regarding establishing and 

implementing a program to provide emergent and elective coronary intervention at a hospital with 

off-site cardiac surgical backup, 2003. 

35. Consultant, T.J. Samson Community Hospital, Glasgow, KY, regarding establishing and 

implementing a program to provide emergent and elective coronary intervention at a hospital with 

off-site cardiac surgical backup, 2003. 

36. Consultant, Regional Cardiac Care Network, PA, regarding their petition to the state Department 

of Health to establish and implement a program to provide emergent and elective coronary 

intervention at a hospital with off-site cardiac surgical backup, 2003. 

37. Peer reviewer, Cardiac Care Network of Ontario Report of Target Setting for Revascularization 

Procedure Capacity, 2003. 

38. Consultant, Mt. Nittany Medical Center, State College, PA, regarding their petition to the state 

Department of Health to establish and implement a program to provide emergent and elective 

coronary intervention at a hospital with off-site cardiac surgical backup, 2003. 

39. Consultant, St. Luke Hospital, Lexington, KY, regarding their petition to the state Department of 

Health to establish and implement a program to provide emergent coronary intervention at a 

hospital with off-site cardiac surgical backup, 2004. 

40. Consultant, Stamford Hospital, Stamford, CT, regarding their petition to the state Department of 

Health to establish and implement a program to provide emergent coronary intervention at a 

hospital with off-site cardiac surgical backup, 2004. 

41. Peer manuscript reviewer, Journal of the American College of Cardiology – 2001-present. 

42. Peer manuscript reviewer, American Journal of Cardiology, 2004-present. 

43. Peer manuscript reviewer, Mayo Clinic Proceedings, 2004-present. 
PAGE 13 OF 21 

TPW 04/13/06 

44. Abstract Reviewer, Transcatheter Cardiovascular Therapeutics Conference, September, 2004 – 43 

abstracts reviewed. 

45. External Reviewer, American College of Cardiology National Cardiovascular Data Registry, Data 

Collection Form Update, 2004. 

46. Consultant, Corazon Corporation, 2004 - present. 

47. Reviewer, Interventional Cardiology Board Certification Examination Questions, American 

Board of Internal Medicine, 2005. 

48. Peer manuscript reviewer, Critical Pathways in Cardiology, 2005-present. 

Manuscripts: 

1. Potchen E, Davis D, Wharton TP Jr, Hill R, Taveras, J. Regional cerebral blood flow in man: I. A 

study of the 133Xenon washout method. Arch Neurol 1969;20:378-83. 

2. Adatepe M, Penkose P, VanAmburg A, Wharton TP Jr, Potchen E. Red cell and plasma protein 

labeling with 113mIndium. Int J Appl Rad Isotopes 1971;22:498-501. 

3. Wharton TP Jr, Cohn PF, Sloss LJ, Angoff GH. Clinical and angiographic implications of a 

depressed echocardiographic ejection fraction in coronary disease. Cath Cardiov Diag 1977;3:259-

66. 

4. Cohen IS, Wharton TP Jr, Neill WA. Pathophysiologic observations on premature opening of the 

aortic valve utilizing a technique for multiplane echocardiographic analysis. Am Heart J 

1979;97:766-72. 

5. Wharton TP Jr, Neill WA, Oxendine JM, Painter LN. Effect of duration of regional myocardial 

ischemia and degree of reactive hyperemia on the magnitude of the initial 201 Thallium defect. 

Circulation 1980;62:516-21. 

6. Neill WA, Wharton TP Jr, Fluri-Lundeen J, Cohen IS. Acute coronary insufficiency - coronary 

occlusion after intermittent ischemic attacks. N Engl J Med 1980;302:1157-62. 

7. Cohen I, Wharton TP Jr. “Duplication” of an aortic cusp: A new M-mode echocardiographic sign 

of intimal tear in aortic dissection. Br Heart J 1980;42:173. 

8. Cohen IS, Widrich W, Duchin KL, Wharton TP Jr, Fluri-Lundeen J, Hargus SM. Acute 

electrophysiologic effects of nadolol (CorgardR

). J Clin Pharmacol 1983;23:93-9. 

9. Cohen IS, Fluri-Lundeen J, Wharton TP Jr. Two dimensional echocardiographic similarity of 

Fabry's disease to cardiac amyloidosis: A function of ultrastructual analogy? J Clin Ultrasound 

1983;11:437-41. 
PAGE 14 OF 21 

TPW 04/13/06 

10. Loscalzo J, Wharton TP Jr, Kirshenbaum J, Levine H, Flaherty J, Topol E, Ramaswamy K, 

Kosowsky B, Salem D, Ganz P, Brinker J, Gurewich V, Muller J. Clot selective thrombolysis with 

pro-urokinase. Circulation 1989;72:776-82. 

11. Stone GW, Marsalese D, Brodie BR, Griffin JJ, Donohue BC, Constantini C, Balestrini C, 

Wharton TP Jr, Esente P, Spain M, Moses J, Nobuyoshi M, Ayres M, Jones D, Mason D, Grines 

L, O'Neill WW, Grines CL, on behalf of the PAMI-II Trial Investigators. A prospective 

randomized evaluation of prophylactic intraaortic balloon counterpulsation in high risk patients 

with acute myocardial infarction treated with primary angioplasty. J Am Coll Cardiol 

1997;29:1459-67. 

12. Grines C, Marsalese D, Brodie B, Griffin J, Donohue B, Constantini C, Balestrini C, Stone G, 

Wharton TP Jr, Esente P, Spain M, Moses J, Nobuyoshi M, Ayres M, Jones D, Mason D, Sachs 

D, Grines L, O’Neill W for the PAMI-II Investigators. Safety and cost-effectiveness of early 

discharge after primary angioplasty in low risk patients with acute myocardial infarction. J Am 

Coll Cardiol 1998;31:967-72. 

13. Wharton TP Jr, McNamara NS, Fedele FA, Jacobs MI, Gladstone AR, Funk EJ. Primary 

angioplasty for the treatment of acute myocardial infarction: Experience at two community 

hospitals without cardiac surgery. J Am Coll Card 1999;33:1257-65. 

14. DeGeare VS, Stone GW, Grines L, Brodie BR, Cox DA, Garcia E, Wharton TP, Boura JA, 

O’Neill WW, Grines, CL. Angiographic and clinical characteristics associated with increased inhospital mortality in elderly patients with acute myocardial infarction undergoing percutaneous 

intervention (a pooled analysis of the primary angioplasty in myocardial infarction trials). Am J 

Cardiol 2000;86:30-4. 

15. Wharton TP Jr, Grines LL, Turco MA, Johnston JD, Souther J, Lew DC, Shaikh AZ, Bilnoski W, 

Singhi SK, Atay AE, Sinclair N, Shaddinger DE, Barsamian M, Graham M, Boura J, Grines CL. 

Primary angioplasty in acute myocardial infarction at hospitals with no surgery on-site (the PAMI 

No SOS study) versus transfer to surgical centers for primary angioplasty. J Am Coll Card 

2004;43:1943-50. 

Textbook Chapters: 

1. Wharton TP Jr. Pulmonary arterial catheterization for diagnosis and treatment of critically ill 

patients. In: MacDonnell K, Fabey P, Segal M, editors. Respiratory Intensive Care. Little Brown 

and Co, 1987. 

2. The Cardiology Roundtable: Myocardial Infarction: Toward a Higher Standard of Care. The 

Advisory Board Co, 1998. Wharton TP Jr, advisor. 

3. McNamara NS, Wharton TP Jr. Critical pathways for primary angioplasty in acute myocardial 

infarction at community hospitals without cardiac surgery. In: Cannon C, O’Gara P, editors. 

Critical Pathways in Cardiology. Philadelphia, PA: Lippincott Williams & Wilkins, 2001:67-94. 
PAGE 15 OF 21 

TPW 04/13/06 

4. Wharton TP Jr, McNamara NS. Primary angioplasty in community hospitals without on-site 

cardiac surgery. In: Tcheng JE, editor. Contemporary Cardiology: Primary Angioplasty in Acute 

Myocardial Infarction. Totowa, NJ: Humana Press Inc, 2002:65-91. 

5. Wharton TP Jr, McNamara NS. Expanding the access to coronary intervention for patients with 

acute coronary syndromes admitted to community hospitals. In: Cannon, C, editor. Acute 

Coronary Syndromes. Totowa, NJ: Humana Press Inc, 2002, 315-331. 

6. Wharton TP Jr, McNamara NS. Primary Angioplasty in acute myocardial infarction at community 

hospitals without cardiac surgery. In Harrison’s ONLINE. Edited by Braunwald E, Fauci A, 

Isselbacher K. Columbus, Ohio: Medical Publishing Division of McGraw-Hill Companies. 2003. 

7. Sinclair N, Wharton TP Jr. Critical pathways for primary angioplasty in acute myocardial 

infarction at community hospitals without cardiac surgery. In: Cannon C, O’Gara P, editors. 

Critical Pathways in Cardiology 2nd Edition. Philadelphia, PA: Lippincott Williams & Wilkins, In 

Press 

Invited Articles, Reviews, Editorials, and Audiotape Interviews: 

1. Amsterdam E, Lakier J, Wharton TP Jr. Managing MI in the community hospital. Patient Care 

1996;30:26. 

2. Overlie PA, Grines CL, Ayres M, Brodie B, Griffin JJ, Holmes DR, O’Neill WW, Stone GW, 

Weaver WD, Wharton TP Jr. Direct PTCA: A Panel Discussion. J Invasive Cardiol 

1997;9(SupplB):53B-58B. 

3. Wharton TP Jr. Primary PTCA primed for AMI at community hospitals. Editorial. Medical 

Tribune 1998;39 No.10:11. 

4. Wharton TP Jr. Point-counterpoint: should primary angioplasty be performed only at hospitals 

with open-heart surgery? No. Physicians Weekly 1998;15:25. 

5. Wharton TP Jr. To cath or not to cath for non-Q-wave MI’s. Editorial. Medical Tribune 1998;39 

No.11:20. 

6. Wharton TP Jr, McNamara NS. Primary angioplasty in the community hospital without on-site 

heart surgery: Current state-of-the art. J Cardiovasc Reviews and Reports 1999;10:545-551. 

7. Wharton TP Jr, McNamara NS. Primary angioplasty should become the standard-of-care at 

qualified hospitals without on-site cardiac surgery. J Intervent Cardiol 2000;13:145-51. 

8. McNamara NS, Wharton TP Jr. Primary Angioplasty At Community Hospitals 

In the 21st Century: Now The Treatment of Choice for Myocardial Infarction at Qualified 

Hospitals Without Cardiac Surgery. Cath Lab Digest November 2000. 
PAGE 16 OF 21 

TPW 04/13/06 

9. McNamara NS, Wharton TP Jr. Response to Dr. Ryan: Primary Angioplasty is the Benchmark for 

the Treatment of AMI and Needs Broader Accessibility. Cath Lab Digest December 2000. 

10. Wharton TP Jr, McNamara NS. Is it Time For Qualified Community Hospitals to Consider NonEmergent Coronary Intervention Without Cardiac Surgery? Cath Lab Digest March 2001. 

11. Wharton TP Jr, McNamara NS. Management of acute coronary syndromes in the community 

hospital without cardiac surgery: how can access to interventional therapy be improved? 

American Journal of Cardiovascular Drugs, 2001;1:375-85. 

12. Wharton TP Jr. Acute myocardial infarction intervention should be performed in select hospitals 

without surgical back-up. Accel audiotape interview, 2002;34 no.7. 

13. McNamara NS, Wharton T. Critical pathways for primary angioplasty in acute myocardial 

infarction at community hospitals without cardiac surgery. Crit Pathways in Cardiol. June 2002; 

74-106. 

14. McNamara NS, Wharton TP Jr., LaRochelle T, DeBoard D. Utilization of intra-aortic balloon 

counterpulsation in patients with acute myocardial infarction that present to community hospitals. 

Crit Pathways in Cardiol 2002; Volume 1, Number 3 

15. Wharton TP Jr., McNamara NS. Evidence and Rationale For Percutaneous Coronary Intervention 

at Qualified Hospitals with Off-Site Cardiac Surgical Backup. J Cardiovasc Manag 2003;14:11-

16. 

16. Wharton TP Jr. How to set up an optimal community hospital angioplasty program. Accel 

audiotape interview 2005;37 no.12. (in preparation) 

17. Wharton TP Jr. Nonemergent percutaneous coronary intervention with off-site surgery backup: an 

emerging new path to access. Crit Pathways in Cardiol 2005;4:98-106. 

18. Wharton TP Jr., Burns, J. e-Consulting helps rural-community hospitals get in the CV game. 

Feature article, Cath Lab Digest October 25, 2005. 

19. Wharton TP Jr. Controversies in Cardiovascular Medicine: Should patients with acute myocardial 

infarction be transferred to a tertiary center for primary angioplasty or receive it at qualified 

hospitals in the community? The case for community hospital angioplasty. Circulation 

2005;112:3509-3534. 

20. Giugliano RP, Lewis WR, Wharton TP Jr. Managing non-ST-elevation acute coronary syndromes. 

Patient Care 2006;40:54-61. 

Letters to the Editor 

1. Wharton TP Jr. Use of cardiac procedures in the United States and Canada [letter]. N Engl J Med 

1997;337:1008. 
PAGE 17 OF 21 

TPW 04/13/06 

2. Wharton TP Jr, McNamara NS, Fedele FA, Jacobs MI, Gladstone AR, Funk EJ. Reply to 

Kereiakes et al: Angioplasty for Acute Myocardial Infarction in Community Hospitals Without 

Surgical Back-Up: Response to Wharton and Angelini Publications “Should Guidelines be 

Changed?: Not Whether but When” [letter]. J Am Coll Card 2000;36:301-3. 

3. Wharton TP Jr. The question of beta blocker use in AMI. Response to Bajina S. Patient Care 

2006;XXXXXXX 

4. Wharton TP Jr. Hubris vs evidence [letter] J Am Coll Card 2006; in press. 

Abstracts: 

1. Potchen E, Davis D, Wharton TP Jr, Clifton J. The effect of Compton scatter on regional cerebral 

blood flow determinations with 133Xenon. Clin Res 1967;15:410. 

2. VanAmburg A, Wharton TP Jr, Wochner D, Potchen E. The binding of Indium 113m to serum 

protein. Clin Res 1968;16:457. 

3. Wharton TP Jr, Sloss L, Cohn P. Can echocardiographic parameters reliably predict generalized 

left ventricular dysfunction? Circulation 1976;54(SuplII):II-111. 

4. Wharton TP Jr, Neill W, Oxendine J, Painter L. Duration of regional ischemia and degree of 

reactive hyperemia affect magnitude of initial 201Thallium defect. Circulation 1979;60:II-173. 

5. Lipinska I, Colbath J, Pelgrund C, Moon C, Wharton TP Jr. Effect of rehabilitation on plasma 

lipids lipoproteins fibrinogen and fibrinolytic activity in patients with coronary artery disease. 

(Poster Session Abstract Book Eighth International Symposium on Atherosclerosis.) Cic Edizioni 

Internationazionali 1988;P-545. 

6. Grines C, Griffin J, Brodie B, Stone G, Donohue B, Balestrini C, Wharton TP Jr, Spain M, 

Shimshak T, Jones D, Mason D, Sachs D, O'Neill W. The second primary angioplasty for 

myocardial infarction study (PAMI-2): Preliminary report. Circulation 1994;90:I-433. 

7. Brodie B, Grines C, Spain M, Griffin J, Balestrini C, Stone G, Constantini C, Esente P, Ayres M, 

Nobuyoshi M, Donohue B, Chelliah N, Rothbaum D, Wharton TP Jr, Jones D, Mason D, Sachs D, 

O'Neill W. A prospective randomized trial evaluating early discharge (day 3) without noninvasive risk stratification in low risk patients with acute myocardial infarction: PAMI-2. J Am 

Coll Cardiol 1995;25:5A. 

8. Griffin J, Grines C, Marsalese D, Spain M, Brodie B, Donohue B, Wharton TP Jr, Stone G, 

Balestrini C, Constantini C, Shimshak T, Delcan J, Jones D, Mason D, Sachs D, O'Neill W. A 

prospective randomized trial evaluating the prophylactic use of balloon pumping in high risk 

myocardial infarction patients: PAMI-2. J Am Coll Cardiol 1995;25:86A. 

9. Wharton TP Jr, Schmitz JM, Fedele FA, McNamara NS, Gladstone AR, Jacobs MI. Primary 

angioplasty in acute myocardial infarction at community hospitals without cardiac surgery: 

Experience in 195 cases. Circulation 1995;92:I-138. 
PAGE 18 OF 21 

TPW 04/13/06 

10. Wharton TP Jr, Marsalese D, Brodie B, Griffin J, Donohue B, Constantini C, Balestrini C, Stone 

G, Esente P, Moses J, McNamara NS, Jones D, Sachs D, Grines C. How often do infarct-related 

arteries show early perfusion without prior thrombolytic therapy, and should these vessels be 

dilated acutely? Results from PAMI-2. Circulation 1995;92:I-530. 

11. Stone G, Marsalese D, Brodie B, Griffin J, Donohue B, Constantini C, Balestrini C, Wharton TP 

Jr, Jones D, Sachs D, Grines C. The routine use of intra aortic balloon pumping after primary 

PTCA improves clinical outcomes in very high risk patients with acute myocardial infarction -- 

Results of the PAMI-2 trial. Circulation 1995;92:I-139. 

12. Stone G, Marsalese D, Brodie B, Griffin J, Donohue B, Constantini C, Balestrini C, Wharton TP 

Jr, Jones D, Sachs D, Timmis G. Is prophylactic IABP use beneficial or harmful in a high risk 

elderly population with acute myocardial infarction? -- PAMI-2 Circulation 1995;92:I-139. 

13. Grines C, Brodie B, Griffin J, Donohue B, Sampaolesi A, Constantini D, Sachs D, Wharton TP Jr, 

Esente P, Spain M, Stone G. Which primary PTCA patients may benefit from new technologies? 

Circulation 1995;92:I-146. 

14. Wharton TP Jr, McNamara NS, Schmitz JM, Fedele FA, Gladstone AR, Jacobs MI. The value of 

immediate coronary angiography with primary PTCA standby in the triage and treatment of acute 

myocardial infarction at community hospitals without heart surgery: Experience in 305 cases. J 

Am Coll Cardiol 1996;27:250A. 

15. Schreiber T, Marsalese D, Griffin J, Donohue B, Sampaolesi A, Constantini C, Stone G, Jones D, 

Sachs D, Mason D, Wharton TP Jr, Rothbaum D, Brodie B, O’Neill W, Grines C. Identification of 

ultra low-risk patients following primary angioplasty for acute myocardial infarction. J Am Coll 

Cardiol 1996;27:83A. 

16. Donohue B, O’Neill W, Jackson E, Brodie B, Griffin J, Balestrini B, Stone G, Wharton TP Jr, 

Jones D, Grines C. Cost analysis of different management strategies for myocardial infarction. J 

Am Coll Cardiol 1996;27:221A. 

17. Grines C, Brodie B, Griffin J, Donohue B, Constantini C, Balestrini C, Stone G, Wharton TP Jr, 

Mitina L, Graham M, Jones D, Sachs D, O’Neill W. Prophylactic intraaortic balloon pumping for 

acute myocardial infarction does not improve left ventricular function. J Am Coll Cardiol 

1996;27:167A. 

18. Wharton TP Jr, McNamara NS, Schmitz JM, Fedele FA, Gladstone AR, Jacobs MI. Direct 

angioplasty in acute myocardial infarction at hospitals without on-site cardiac surgery: Experience 

in 227 cases. J Invasive Cardiol 1996;8:73. 

19. Wharton TP Jr, McNamara NS, Schmitz JM, Fedele FA, Jacobs MI, Gladstone AR, Funk EJ, 

Corbett P. Early coronary patency after high-dose heparin without thrombolytic therapy in 158 

patients with acute myocardial infarction. Circulation 1996;94:I-553. 
PAGE 19 OF 21 

TPW 04/13/06 

20. McNamara NS, Hiett D, Allen B, Chaille B, Vigdor C, Corbett P, Schmitz JM, Fedele FA, 

Wharton TP Jr. Can community hospitals provide effective primary PTCA coverage at all hours? J 

Am Coll Cardiol 1997;29:91A. 

21. Wharton TP Jr, McNamara NS, Schmitz JM, Fedele FA, Jacobs MI, Gladstone AR, Funk EJ, 

Corbett P. Primary PTCA in patients with acute MI without ST elevation: A community hospital 

experience. Circulation 1997;96:I-595. 

22. Wharton TP Jr, Johnston JD, Turco MA, Souther J, Lew D, Bilnoski W, Singhi S, McNamara NS, 

Graham M, Grines L, Weaver W, Grines C. Primary angioplasty for acute myocardial infarction at 

hospitals with no surgery on site: The prospective multicenter PAMI-No SOS Registry. J Am Coll 

Card 1998;31:210A. 

23. Wharton TP Jr, McNamara NS, Lew D, Tomassetti J, Turco M, McGarvey J, Shaddinger D, 

Shaikh A, Bramlett K, Bilnoski W, McCurley E, Atay A, Murrah E, Graham M, Grines C. 

Cardiogenic shock at community hospitals with no surgery on site: Outcomes after primary 

angioplasty in 101 patients in a multicenter registry. Circulation 1998;98:I-307-8. 

24. Wharton TP Jr, McNamara NS, Fedele FA, Schmitz JM, Jacobs MI, Gladstone AR, Funk EJ, 

Corbett P. Emergency coronary bypass after primary PTCA at hospitals without open-heart 

surgery. Circulation 1998;98:I-307. 

25. McNamara NS, Wharton TP Jr, Johnston J, Turco M, Souther J, Lew D, Bilnoski W, Singhi S, 

Barsamian M, Graham M, Grines L. Can hospitals with no surgery on site provide effective 

infarct intervention at all hours? The PAMI-No SOS experience. Circulation 1998;98:I-306-7. 

26. Johnston J, O'Neill W, Slota P, Wharton TP Jr, Turco M, Stone G, Brodie B, Barsamian M, 

Graham M, Grines L, Grines C. Primary PTCA at community hospitals without surgical backup is 

performed as effectively and with less delay compared to tertiary care centers. Circulation 

1998;98:I-770. 

27. McGarvey J, Johnston J, Souther J, Shaddinger D, Graham M, Grines L, Barsamian M, Wharton 

TP Jr. Primary PTCA in acute myocardial infarction in diabetics at community hospitals with no 

surgery on site provides successful treatment with low adverse clinical events. Circulation 

1998;98:I-308. 

28. Lew DC, Tomassetti J, Rosado JR, Chandler K, Grines CL, Wharton TP Jr. Outcome of primary 

PTCA (PTCA) and emergency PTCA (E-PTCA) at a community hospital without on-site surgery. 

J Invasive Cardiol 1998. 

29. Wharton TP Jr, Johnston JD, Turco MA, Souther J, Lew DC, Bilnoski W, Shaikh AZ, Singhi SK, 

Atay AE, Slota P, McGarvey JFX Jr, Fedele FA, McNamara NS, Shaddinger DE, Barsamian M, 

Graham M, Grines LL, Grines, CL. Primary angioplasty for acute myocardial infarction with no 

surgery on site: Outcomes, core angiographic analysis, and six-month follow-up in the 500-patient 

prospective PAMI--No S.O.S. Registry. J Am Coll Cardiol 1999;33:352A-3A. 
PAGE 20 OF 21 

TPW 04/13/06 

30. McGarvey JFX Jr, Johnston JD, Souther J, Shaddinger DE, Barsamian M, Graham M, Grines LL, 

Wharton TP. Coronary stenting reduces mortality in diabetics with acute myocardial infarction: 

6-month follow-up in the 500 patient prospective PAMI-No SOS Registry. Circulation 

1999;100:I-139. 

31. McNamara NS, Scoggins A, Hiett D, Benson K, Rines L, Reagan K, Fedele FA, Corbett P, 

Wharton TP Jr. Improving angioplasty results at hospitals without cardiac surgery using ongoing 

outcomes monitoring and evaluation. Am J Cardiol 1999;84:73P. 

32. Grines LL, Cox DA, Garcia E, Johnston JD, Turco MA, Wharton TP Jr, Griffin JJ, McGarvey J Jr, 

Shaddinger D, Graham M, Boura JA, O’Neill WW, Stone G, Grines CL. Divergent effects of 

“discretional” vs “mandated” stenting on acute myocardial infarction survival in women. J Am 

Coll Cardiol 2000;35:56A. 

33. Grines LL, Wharton TP Jr, Balestrini C, Westerhausen DR Jr, Turco MA, Niemela M, Logermann 

TL, Hanlon TH, Boura JA, Grines, CL. Should high-risk acute myocardial infarction patients 

admitted to non-surgical hospitals be transferred for primary PTCA or receive it on-site? 

Circulation 2000;102:II-386. 

34. Wharton TP Jr, McNamara NS, Friedman S, Kenady B, Weinberg B, Huser S, Souther SJ, 

Headrick M, Gill SK, Sayeed J, West S, Brush J, Angel J, Scanlan D. Non-emergent coronary 

intervention without cardiac surgery on site: Outcomes in 1,501 patients in the US. Circulation 

2000;102:II-731-2. 

35. McNamara NS, LaRochelle T, DeBoard D, Jack J, Wason L, Benson KF, Lanseigne E, Gagnon R, 

Stevens A, Cronin S, Coffey S, Fedele FA, Anderson JE, Wharton TP Jr. Biologic variability of 

response to GP-IIb/IIIa platelet inhibitors supports in-lab rapid platelet function assay to optimize 

platelet inhibition during PCI. Am J Cardiol 2001;88 (suppl 5A):97G. 

36. McNamara NS, Wharton TP Jr., Anderson JE , Fedele FA, DeBoard D, LaRochelle T, Wason, L, 

Lanseigne E, Gagnon R, Benson KF, Coffey S, Lannon, W, Cronin S. Primary percutaneous 

coronary intervention for cardiogenic shock at a community hospital with off-site cardiac surgical 

backup. Am J Cardiol 2002;90 (suppl 6A) 181-2H. 

37. Kutcher MA, Klein LW, Wharton TP, Applegate RJ, Brindis RG, Shaw RE, Weintraub WS. 

Clinical outcomes in coronary angioplasty centers with off site versus on site cardiac surgery 

capabilities: a preliminary report from the American College of Cardiology National 

Cardiovascular Data Registry. J Am Coll Cardiol 2004;43:96A. 

38. Malenka DJ, Silver T, Kellet M, Hearne M, Verlee P, Wharton TP, Robb JF, Watkins M. 

Decreasing mortality in primary percutaneous coronary interventions in Northern New England is 

related to efforts at regional quality improvement. J Am Coll Cardiol 2004;43:405A. 
PAGE 21 OF 21 

TPW 04/13/06 

39. Malenka DJ, Leavitt BJ, Hearne MJ, Robb JF, Baribeau YR, Ryan TJ, Helm RE, Kellet MA, 

Dauerman HL, Dacey LJ, Silver MT, Ver Le PN, Weldner PW, Wharton TP, Niles NW, O’Meara 

JR, Watkins MW, Hettleman BD, Olmstead EM, O’Conor GT. Long-term survival for patients 

with multivessel coronary disease is better following CABG than PCI: An analysis of BARI-like 

patients in NNE from 1994-2001. Circulation 2004;110:III-419. 

40. Foster JK, Klein LW, Veledar E, Kolm P, Zhang Z, Anderson GT, Brindis RG, Mitchel KR, 

Hewitt KM, Krone R, Wharton TP Jr, Kutcher M, Weintraub WS. On-site Surgical Backup as a 

Predictor of Mortality Among PCI Patients with STEMI, NSTEMI, or No AMI. Circulation 

2005;112:II-737. 

41. Ryan TJ Jr, Robb JF, Kellett MA Jr, Hearne MJ, Silver TM, Phillips W, Wharton TP Jr, Piper 

WD, Malenka DJ. Angiographic success rates with chronic total occlusions: little change despite a 

decade of experience. J Am Coll Cardiol 2006;47:252A. 

42. Fitts JM, Silver TM, Hearne MJ, Ryan TJ Jr, Robb JF, Kellett MA Jr, Wharton TP Jr, Phillips W, 

Piper WD, Malenka DJ. Primary percutaneous coronary intervention for acute myocardial 

infarction in women versus men 1995-2004. J Am Coll Cardiol 2006;47:184A. 

Invited Lectures (Most Recent 11 Years): 

1. “Primary Angioplasty in Acute Myocardial Infarction.” Cardiology Symposium, Waterville 

Valley, NH, February 1995. 

2. “A Community Hospital Experience with Primary Angioplasty.” Cardiology Grand Rounds, Tufts 

University--New England Medical Center, Boston, MA, September 19, 1995. 

3. “Primary Angioplasty: The Treatment of Choice for Acute M.I.?” Cardiac Surgery Rounds, 

Catholic Medical Center, Manchester, NH, January 1996. 

4. “Direct PTCA in Acute Myocardial Infarction.” Symposium Faculty Panelist, Transcatheter 

Cardiovascular Therapeutics Convention; Washington DC, February 29, 1996. 

5. “Is Primary PTCA the Treatment of Choice for Acute M.I.? Evidence From PAMI, GUSTO, and 

Community Hospitals.” Metro West Medical Center, Framingham, MA, April 16, 1996. 

6. “GUSTO, PAMI, and Primary Angioplasty at Community Hospitals Without Heart Surgery.” 

Cardiology Symposium, St. James Hospital and Health Centers, Chicago Heights, IL, June 1, 

1996. 

7. “Primary Angioplasty: A Community Hospital Experience.” Cardiology Rounds, Lahey Clinic, 

Burlington, MA, July 18, 1996. 

8. “Primary PTCA Is the Treatment of Choice for Acute M.I. Evidence From PAMI, GUSTO, and 

Exeter-Across-The-Sea.” Western England Regional Cardiology Conference, Exeter Hospital, 

Exeter, England, September 19, 1996. 
PAGE 22 OF 21 

TPW 04/13/06 

9. “Primary Angioplasty and Lytic Therapy in Acute Myocardial Infarction Without On-Site 

Surgical Support: Evidence from PAMI, GUSTO, and Community Hospitals.” Cardiology 

Symposium, New Britain General Hospital, New Britain, CT, October 28, 1996. 

10. “Is Primary PTCA the Treatment of Choice for Acute M.I.? Evidence From PAMI, GUSTO, and 

Community Hospitals.” Medical Grand Rounds, Portsmouth Regional Hospital, Portsmouth, NH, 

October 1, 1996. 

11. “Is Primary PTCA the Treatment of Choice for Acute M.I.? Evidence From PAMI, GUSTO, and 

Community Hospitals.” Medical Grand Rounds Elliot Hospital, Manchester, NH, October 17, 

1996. 

12. “A Community Hospital Experience With Primary PTCA.” Medical Grand Rounds, Anna Jacques 

Hospital, Newburyport MA, October 21, 1996. 

13. “Primary Angioplasty and Lytic Therapy in Acute Myocardial Infarction Without On-Site 

Surgical Support: Evidence from PAMI, GUSTO, and Community Hospitals.” Cardiology Grand 

Rounds, Bay State Medical Center, Springfield, MA, November 18, 1996. 

14. “GUSTO, PAMI, and Primary Angioplasty at Community Hospitals Without Heart Surgery.” 

Parkland Hospital, Derry, NH, December 3, 1996. 

15. “Is Primary PTCA the Treatment of Choice for Acute M.I.? Evidence From PAMI, GUSTO, and 

Community Hospitals.” Medical Grand Rounds, Exeter Hospital, Exeter, NH, December 17, 1996. 

16. “Is Primary PTCA the Treatment of Choice for Acute M.I. at Community Hospitals?” Medical 

Grand Rounds, Doylestown Hospital, Doylestown, PA, February 25, 1996. 

17. “Mechanical Intervention for Acute Myocardial Infarction.” Luncheon Panelist, American 

College of Cardiology 46th Annual Scientific Sessions, Anaheim, CA, March 17, 1997. 

18. “Heart Attack: Preventing and Treating.” Spring 1997 Health Education Series, Healthreach 

Initiative, Exeter Hospital, Exeter, NH, April 22, 1997. 

19. “Interpretation of the 12-Lead EKG.” 1997 Paramedic Refresher Program. Exeter Hospital, 

Exeter, NH, April 30, 1997. 

20. “Primary PTCA: Is It the Treatment of Choice for Acute Myocardial Infarction at Community 

Hospitals?” Spring Symposium for Cardiopulmonary Wellness, New Hampshire Society for 

Cardiopulmonary Rehabilitation, Bedford, NH, May 8,1997. 

21. “Primary PTCA: A Community Hospital Experience.” Eighth Annual Lahey Hitchcock Clinic 

Symposium on Cardiovascular Disease: State of the Art 1997, Brewster, Cape Cod, MA, June 23, 

1997. 
PAGE 23 OF 21 

TPW 04/13/06 

22. “Primary Intervention for Acute Myocardial Infarction at Exeter Hospital: Past, Present, and 

Future.” Medical Grand Rounds, Exeter Hospital, Exeter, NH, October 21, 1997. 

23. “Primary PTCA: Is It the Treatment of Choice for Acute Myocardial Infarction at Community 

Hospitals?” Medical Grand Rounds, Charlton Memorial Hospital, Fall River, MA, November 4, 

1997 

24. “The AIR PAMI No S.O.S.! Registry: A Progress Report.” American Heart Association Satellite 

Conference, Orlando, FL, November 10, 1997. 

25. “Primary Angioplasty: Where, How, and When?” Cardiology Fireside Panel, American College 

of Cardiology 47th Annual Scientific Sessions, Atlanta, GA, March 29, 1998. 

26. “Primary PTCA in Centers Without Surgical Backup.” Meet the Experts, American College of 

Cardiology 47th Annual Scientific Sessions, Atlanta, GA, April 1, 1998. 

27. “PAMI No S.O.S.! Is Primary Intervention the Treatment of Choice for Acute Myocardial 

Infarction at Community Hospitals?” Medical Grand Rounds, St Luke’s Hospital, New Bedford, 

MA, April 23, 1998. 

28. “Is Primary Intervention the Treatment of Choice for Acute Myocardial Infarction at Community 

Hospitals? Evidence from the PAMI No S.O.S.! Study.” Cardiology Symposium, 

Cardiovascular Institute of the South, New Iberia, LA, August 25, 1998. 

29. “Infarct Angioplasty Without Onsite Surgery: Is It Right for Michigan?” Eleventh Annual New 

Directions in Myocardial Revascularization Symposium—A Live Case Demonstration Course; 

William O’Neill, Course Director. Hyatt Regency, Dearborn, MI, September 15, 1998. 

30. “Primary Angioplasty for Acute Myocardial Infarction at Hospitals With No Surgery On Site: 

The Prospective Multicenter PAMI-No SOS Registry.” British Cardiovascular Intervention 

Society Autumn 1998 Meeting. Grand Hotel, Torquay, UK, October 23, 1998, 

31. “A Can of Worms Opened? Intervention for ‘Trial Negative’ Acute Coronary Syndromes.” 

British Cardiovascular Intervention Society Autumn 1998 Meeting. Grand Hotel, Torquay, UK, 

October 23, 1998, 

32. “Primary Angioplasty in Acute Myocardial Infarction with No Surgery On Site [PAMI – No 

S.O.S.!]: Four Exeter Presentations to the American Heart Association. Medical Grand Rounds, 

Exeter Hospital, Exeter NH, November 17, 1998. 

33. “The Changing Role of Primary Angioplasty in The Treatment of Acute Myocardial Infarction at 

Community Hospitals.” Medical Grand Rounds, Frisbie Memorial Hospital, Rochester, MA, 

December 10, 1998 
PAGE 24 OF 21 

TPW 04/13/06 

34. “Primary PTCA is the Treatment of Choice for AMI at Qualified Hospitals Without Onsite 

Surgery: The Exeter/Portsmouth Experience.” Interventional Cardiology: Controlling Costs and 

Improving Outcomes. Cambridge Health Resources Symposium, Orlando, FL, January 25-26, 

1999. 

35. “Primary PTCA at Hospitals Without Surgical Backup is Performed as Effectively and with Less 

Delay Compared to Tertiary Care Centers.” Interventional Cardiology: Controlling Costs and 

Improving Outcomes. Cambridge Health Resources Symposium, Orlando, FL, January 25-26, 

1999. 

36. “Primary Angioplasty: Who, Where, When.” Luncheon Panelist, American College of 

Cardiology 48th Annual Scientific Sessions, New Orleans, LA, March 10, 1999. 

37. “Primary PTCA at community hospitals without surgical backup is performed as effectively and 

with less delay compared to tertiary care centers: Evidence from the PAMI Studies.” Medical 

Grand Rounds, Norwood Hospital, Norwood MA, March 25, 1999 

38. “Primary PTCA is the Treatment of Choice for Acute Myocardial Infarction at Qualified Hospitals 

Without On-Site Surgery.” Medical Grand Rounds, Stamford Hospital, Stamford CT, May 5, 

1999 

39. “Performing PTCA in the Community Hospital.” Primary PTCA: The Expert Approach. The 

Cardiovascular Training and Education Center at the Washington Hospital Center Symposium, 

Washington, DC, May 6, 1999. 

40. “Properly Utilizing Adjunct Pharmacology Before, During, and After Mechanical Reperfusion 

Therapy.” Primary PTCA: The Expert Approach. The Cardiovascular Training and Education 

Center at the Washington Hospital Center Symposium, Washington, DC, May 6, 1999. 

41. “Primary Angioplasty in Acute Myocardial Infarction: Strategy and Logistic.” Primo Seminario 

Internazionale—Clinica Montevergine: L’Infarto Miocardio Acuto. Symposium, Avellino, Italy, 

June 12, 1999 

42. “Performing PTCA in the Community Hospital.” Primary PTCA: The Expert Approach. The 

Cardiovascular Training and Education Center at the Washington Hospital Center Symposium, 

Washington, DC, August 17, 1999. 

43. “Properly Utilizing Adjunct Pharmacology Before, During, and After Mechanical Reperfusion 

Therapy.” Primary PTCA: The Expert Approach. The Cardiovascular Training and Education 

Center at the Washington Hospital Center Symposium, Washington, DC, August 17, 1999. 

44. “Treatment Alternatives in Women with Acute Myocardial Infarction: Primary Angioplasty, and 

Primary Stenting.” The Women’s Cardiovascular Heathcare Initiative: Issues, Clinical Trials, 

and Future Directions. Transcatheter Cardiovascular Therapeutics Convention, Washington D.C., 

September 23, 1999. 
PAGE 25 OF 21 

TPW 04/13/06 

45. “Acute Infarct Angioplasty.” Moderator, Lunchtime Breakout Session. Transcatheter 

Cardiovascular Therapeutics Convention, Washington D.C., September 24, 1999. 

46. “Primary PTCA Tips and Techniques: Roundtable Discussion with the Experts.” Panelist, 

Concurrent Session. Transcatheter Cardiovascular Therapeutics Convention, Washington D.C., 

September 25, 1999. 

47. “Successful Strategies for Providing Primary Angioplasty at a Community Hospital: The Exeter 

Hospital Experience.” The Dr. Arfan Al-Hani Cardiology Symposium, St. James Hospital and 

Health Centers, Chicago Heights, IL, October 16, 1999. 

48. “Community Hospital Approach to the Treatment of the AMI Patient: The Emerging Role of 

Primary Angioplasty.” Optimizing Outcomes in the MI Patient: A Multidisciplinary Approach. 

AHA Satellite Symposium, Atlanta, GA, Nov 8, 1999 

49. “Heart Attacks: How to Prevent Them, and What to Do if You Have One.” Exeter Hospital 

Community Education Series, November 15, 1999. 

50. “Primary PTCA at a Community Hospital Without On-Site Cardiac Surgery.” Northern Indiana 

Education Foundation Continuing Medical Education Program, St. Anthony Hospital, Michigan 

City, IN, January 25, 2000. 

51. “Primary PTCA is the Treatment of Choice for Acute Myocardial Infarction at Qualified Hospitals 

Without Onsite Cardiac Surgery.” Valley Medical Center, Pleasanton, CA, February 10, 2000. 

52. “Coronary Angioplasty Without Surgical Backup.” Symposium: Coronary Intervention Problem 

Solving, American College of Cardiology 49th Annual Scientific Sessions, Anaheim, CA, March 

13, 2000. 

53. “Primary Angioplasty: Who, Where, When.” Luncheon Panelist, American College of 

Cardiology 49th Annual Scientific Sessions, Anaheim, CA, March 15, 2000. 

54. “Extending Angioplasty to Hospitals Without Cardiac Surgery.” Cardiovascular Thought Leaders 

Summit III, William O’Neill, MD, William Beaumont Hospital, Chair, Las Vegas, NV, April 1, 

2000. 

55. “Treatment Alternatives in Women with Acute MI: Thrombolysis, Primary Angioplasty, or 

Primary Stenting.” Cardiovascular Interventions: Technology at the Summit X, Aspen, CO, June 

30, 2000. 

56. “Primary Angioplasty I Community Hospitals Without Cardiac Surgery.” Cardiovascular 

Interventions: Technology at the Summit X, Aspen, CO, June 30, 2000. 

57. “Primary Angioplasty is the Treatment of Choice for Acute MI at Qualified Community 

Hospitals.” Grand Rounds, Our Lady of Resurrection Hospital, Chicago, October, 2000. 
PAGE 26 OF 21 

TPW 04/13/06 

58. “Controversy: PTCA in Community Hospitals.: 12th Annual Conference, Michigan Chapter, 

American College of Cardiology. Traverse City, MI, October 15, 2000. 

59. “Acute Infarct Angioplasty and the Thrombus-Containing Lesion.” Moderator, Lunchtime 

Breakout Session. Transcatheter Cardiovascular Therapeutics Convention, Washington D.C., 

October 19, 2000. 

60. Primary Angioplasty: Poster Session Moderator. Transcatheter Cardiovascular Therapeutics 

Convention, Washington D.C., October 20, 2000. 

61. “Primary Angioplasty Can Be Done At Least As Well At Hospitals Without Surgical Back-Up as 

in Tertiary Centers—Final Results of the PAMI-No S.O.S. Study, and a Call For New Standards. 

Transcatheter Cardiovascular Therapeutics Convention, Washington D.C., October 21, 2000. 

62. “Angioplasty for Acute Myocardial Infarction at the Community Hospital.” Medical Grand 

Rounds, Lowell General Hospital, Lowell, MA, March 21, 2001. 

63. “Angioplasty With Off-Site Cardiac Surgery Backup: Current Data and Status.” New Jersey 

Department of Health, September 7, 2001. 

64. “Expanding Access for Primary PCI in AMI: Open It Up—Involve the Community!” PointCounterpoint, Transcatheter Cardiovascular Therapeutics Convention, Washington D.C., 

scheduled September 13, 2001. 

65. “AMI Intervention in Labs Without Open Heart Surgical Back-up.” Symposium: Local 

Percutaneous Intervention for Acute Myocardial Infarction. Sponsored by Ohio Quality Cardiac 

Care Foundation, Ohio Chapter of the American College of Cardiology, Ohio Hospital 

Association, Ohio State Medical Association, Columbus, OH, September 28, 2001. 

66. “Expanding the Access to Primary Angioplasty in Acute MI at Qualified Hospitals with Off-Site 

Cardiac Surgical Backup.” Testimony before the Certificate of Needs Committee, Michigan 

Department of Health, Lansing, MI, December 11, 2001. 

67. “Rationale for and Evolution of Percutaneous Coronary Intervention at Hospitals with Off-Site 

Cardiac Surgical Backup.” Cardiology Meeting, Kingman Regional Medical Center, Kingman 

AZ, January 30, 2002 

68. “Non-Emergent Coronary Intervention with Off-Site Cardiac Surgery.” Medical Grand Rounds, 

Verde Valley Medical Center, Cottonwood AZ, February 1, 2002 

69. “Primary and Non-Emergent PCI at Hospitals With Off-Site Cardiac Surgical Backup: Rationale 

and Evidence.” Medical Conference, Overlook Hospital, Summit, NJ, February 6, 2002. 

70. “Expanding Access for Primary PCI in AMI: Open It Up—Involve the Community!” PointCounterpoint, New Jersey Interventional Cardiology Society, Summit, NJ, February 6, 2002. 
PAGE 27 OF 21 

TPW 04/13/06 

71. “Acute Myocardial Infarction Intervention Should Be Performed in Hospitals Without Surgical 

Back-Up.” Protagonist, Controversies in Interventional Cardiology. American College of 

Cardiology 51st Annual Scientific Sessions, Atlanta, GA, March 18, 2002. 

72. “Percutaneous Coronary Intervention for Acute MI at Hospitals without Onsite Bypass Surgery.” 

12th Annual Meeting of the Ohio Chapter of the American College of Cardiology, Huron, OH, 

June 8, 2002. 

73. “Trends in Community Based Cardiac Care: Primary Percutaneous Coronary Intervention (PCI) – 

Implications for IAB Therapy.” Datascope Global Sales and Clinical Meeting, Seabrook Island, 

SC, July 22, 2002. 

74. “Expanding Primary PCI To The Masses: A Time-Dependent Debate. Hospitals Without Surgery 

On Site Are A Better Way To Go!” Transcatheter Cardiovascular Therapeutics Convention, 

Washington D.C., September 28, 2002. 

75. Discussant, Acute Myocardial Infarction Question and Answer Panel II. Transcatheter 

Cardiovascular Therapeutics Convention, Washington D.C., September 28, 2002. 

76. “Expanding Primary PCI To The Masses.” Peruvian Cardiology Interventionist Symposium, 

presentation by telephone with slides shown in Peru, October 18, 2002. 

77. “Percutaneous Coronary Intervention with Off-Site Surgical Backup.” Grand Rounds, Memorial 

Herman Hospital, Houston, TX, January 24, 2003. 

78. “Primary and Non-Emergent PCI at Hospitals With Off-Site Cardiac Surgical Backup: Rationale 

and Evidence.” Grand Rounds, Uniontown Hospital, Uniontown, PA, February 13, 2003. 

79. “Primary PCI Is The New Standard Of Care For Acute Myocardial Infarction: Rationale And 

Evidence.” Grand Rounds and repeated evening dinner presentation, Eastern Maine Medical 

Center, Lewiston, ME, March 13,2003. 

80. “Primary and Non-Emergent PCI at Hospitals With Off-Site Cardiac Surgical Backup: Rationale 

and Evidence.” Medical Conference, The Woodlands Hospital, The Woodlands, TX. May 21, 

2003. 

81. “Primary and Non-Emergent PCI at Hospitals With Off-Site Cardiac Surgical Backup: Rationale 

and Evidence.” Medical Conference, Lawrence Memorial Hospital, Lawrence, KN, June 8, 2003. 

82. “Aspirin Resistance: A Commonplace Occurrence. Incidence, Consequences, and Potential New 

Directions for Treatment of Coronary Disease.” Fisher Healthcare Conference: “The Next 

Adventure,” Woodlands, TX, August 5, 2003. 
PAGE 28 OF 21 

TPW 04/13/06 

83. Moderator, Intervention in Acute Myocardial Infarction abstract session. Transcatheter 

Cardiovascular Therapeutics Convention, Washington D.C., September 15, 2003. 

84. Case Presenter, “Angioplasty and the Thrombus-Containing Lesion.” Transcatheter 

Cardiovascular Therapeutics Convention, Washington D.C., September 16, 2003. 

85. “Angioplasty with Off-Site Open Heart Surgery Support: Is it Time Yet?” The Heart of Your 

Cardiovascular Program: Hospitals & Physicians as Partners. The Corazon Conference, Atlanta, 

GA, October 23, 2003. 

86. “Acute Myocardial Infarction.” Luncheon Panelist, American College of Cardiology 53rd Annual 

Scientific Sessions, New Orleans, LA, March 8, 2004. 

87. “Evidence-Based Medicine Review, and Implications of the 2004 ACC/AHA STEMI 

Guidelines.” Discussant, Plenary Session. Transcatheter Cardiovascular Therapeutics 

Convention, Washington D.C., September 27, 2004. 

88. Moderator, Vascular Access and Complications abstract session. Transcatheter Cardiovascular 

Therapeutics Convention, Washington D.C., September 30, 2004. 

89. Moderator and discussant, “Cutting Edge Strategies in Acute Coronary Syndromes and 

Myocardial Infarction.” Transcatheter Cardiovascular Therapeutics Convention, Washington 

D.C., October 1, 2004. 

90. “Broadening the Reach of Primary PCI I: Angioplasty at Non-Surgical Hospitals – From 

Single Site Experiences to PAMI No SOS: Personal Perspectives.” Transcatheter Cardiovascular 

Therapeutics Convention, Washington D.C., October 1, 2004. 

91. Moderator, American College of Cardiology National Cardiovascular Data Registry Meeting: 

“States Exercising Quality Improvement.” American College of Cardiology 54th Annual 

Scientific Sessions, Orlando, FL, March 5, 2005. 

92. “How to Set Up an Optimal Community Hospital Angioplasty Program.” Meet the Experts, 

American College of Cardiology 54th Annual Scientific Sessions, Atlanta, GA, April 1, 2005. 

93. “Primary and Elective PCI with Off-Site Cardiac Surgery Backup: Rationale and Evidence (and a 

critique of the 2005 PCI Guidelines!)” American Academy of Cardiovascular Administrators 17th

Leadership Conference, Atlanta, GA, March 10, 2006. 

94. “Elective Percutaneous Coronary Intervention Without On-Site Surgery.” American College of 

Cardiology 5th Annual Scientific Sessions, Atlanta GA, March 14, 2006.